Phase II Study of Single-Agent Pegylated Liposomal Doxorubicin HCl (PLD) in Metastatic Breast Cancer After First-Line Treatment Failure

Publisher： Karger

E-ISSN： 2296-5262|27|5|441-446

ISSN： 2296-5270

Source： Oncology Research and Treatment, Vol.27, Iss.5, 2004-10, pp. : 441-446

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Multicenter Phase II Study of Pegylated Liposomal Doxorubicin in Combination with Vinorelbine as First-Line Treatment in Elderly Patients with Metastatic Breast Cancer

By  

Oncology Research and Treatment, Vol. 32, Iss. 1-2, 2009-01 ,pp. : 18-24

Karger

Access to resources Recommend Favorite

Phase II Trial of Pegylated Liposomal Doxorubicin-Cyclophosphamide Combination as First-Line Chemotherapy in Older Metastatic Breast Cancer Patients

By  

Oncology, Vol. 73, Iss. 3-4, 2008-04 ,pp. : 210-214

Karger

Access to resources Recommend Favorite

Phase II Study of Concurrent Administration of Doxorubicin and Docetaxel as First-Line Chemotherapy for Metastatic Breast Cancer

By  

Oncology, Vol. 64, Iss. 2, 2003-02 ,pp. : 124-130

Karger

Access to resources Recommend Favorite

Weekly Docetaxel and Gemcitabine as First-Line Treatment for Metastatic Breast Cancer: Results of a Multicenter Phase II Study

By  

Oncology, Vol. 68, Iss. 4-6, 2005-08 ,pp. : 438-445

Karger

Access to resources Recommend Favorite

Prospective Multicenter Randomized Phase III Study of Weekly versus Standard Docetaxel plus Doxorubicin (D4) for First-Line Treatment of Metastatic Breast Cancer

By  

Oncology, Vol. 79, Iss. 3-4, 2011-03 ,pp. : 204-210

Karger

Access to resources Recommend Favorite